Citalopram

Generic Name: Citalopram

Brand Names: Celexa, Ctp

Drug Type: Small Molecule

Chemical Formula: C_₂₀H_₂₁FN_₂O

CAS Number: 59729-33-8

Unique Ingredient Identifier: 0DHU5B8D6V

Background: Citalopram is an antidepressant belonging to the class of selective serotonin-reuptake inhibitors (SSRIs) widely used to treat the symptoms of depression. It is a racemic bicyclic phthalate derivate and is the only compound with a tertiary amine and 2 nitrogen-containing metabolites among all SSRIs. Citalopram enhances serotonergic transmission through the inhibition of serotonin reuptake, and among all the SSRIs, citalopram appears to be the most selective toward serotonin reuptake inhibition. Specifically, it has a very minimal effect on dopamine and norepinephrine transportation and virtually no affinity for muscarinic, histaminergic, or GABAergic receptors.

Citalopram was approved by the FDA in 1998 for the treatment of depression in adults 18 years or older.

Indication: Citalopram is approved by the FDA for treating adults with major depressive disorder. It has also been used off-label to treat various diseases, including but not limited to sexual dysfunction, ethanol abuse, psychiatric conditions such as obsessive-compulsive disorder (OCD), social anxiety disorder, panic disorder, and diabetic neuropathy.

Associated Conditions: Alcohol Abuse, Anorexia Nervosa (AN), Binge Eating Disorder (BED), Bulimia Nervosa, Depression, Diabetic Neuropathies, Generalized Anxiety Disorder, Major Depressive Disorder (MDD), Obsessive Compulsive Disorder (OCD), Panic Disorder, Post Traumatic Stress Disorder (PTSD), Premature Ejaculation, Premenstrual Dysphoric Disorder (PMDD), Separation Anxiety Disorder, Social Anxiety Disorder (SAD)

Associated Therapies: -

Clinical Trials

Pipamperone/Citalopram (PipCit)Versus Citalopram in the Treatment of Major Depressive Disorder(MDD)

Phase 2

Completed

Conditions: Depression

Interventions: Drug: Citalopram + Pipamperone
Drug: Citalopram

First Posted Date: 2008-05-06

Last Posted Date: 2011-05-02

Lead Sponsor: PharmaNeuroBoost N.V.

Target Recruit Count: 165

Registration Number: NCT00672659

Locations: 🇬🇧
CPSResearch, Glasgow, Scotland, United Kingdom

A Study Comparing Duloxetine to Other Antidepressants in the Treatment of Severe Depression

Phase 4

Completed

Conditions: Depression

Interventions: Drug: duloxetine
Drug: citalopram
Drug: fluoxetine
Drug: sertraline
Drug: paroxetine

First Posted Date: 2008-04-25

Last Posted Date: 2010-06-15

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 750

Registration Number: NCT00666757

Locations: 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Brown Deer, Wisconsin, United States

Functional MRI Evaluation of the Effect of Citalopram in Autism Spectrum Disorders

Phase 1

Completed

Conditions: Autism Spectrum Disorders

Interventions: Drug: Citalopram
Drug: Placebo

First Posted Date: 2008-02-07

Last Posted Date: 2012-10-08

Lead Sponsor: University of North Carolina, Chapel Hill

Target Recruit Count: 12

Registration Number: NCT00609531

Locations: 🇺🇸
UNC-Chapel Hill, Chapel Hill, North Carolina, United States

Effectiveness of Methylphenidate in Improving Cognition and Function in Older Adults With Depression

Phase 4

Completed

Conditions: Depression

Interventions: Drug: Methylphenidate (MPH)
Drug: Citalopram
Drug: Placebo

First Posted Date: 2008-01-28

Last Posted Date: 2018-01-11

Lead Sponsor: University of California, Los Angeles

Target Recruit Count: 181

Registration Number: NCT00602290

Locations: 🇺🇸
UCLA Semel Institute - Neuropsychiatric Institute (NPI), Los Angeles, California, United States

Dementia Antipsychotics And Antidepressants Discontinuation Study

Phase 4

Completed

Conditions: Dementia

Interventions: Drug: Risperidone
Drug: Escitalopram
Drug: Citalopram
Drug: Sertraline
Drug: Paroxetine

First Posted Date: 2008-01-15

Last Posted Date: 2011-02-23

Lead Sponsor: Sykehuset Innlandet HF

Target Recruit Count: 149

Registration Number: NCT00594269

Locations: 🇳🇴
Sykehuset Innlandet HF, Reinsvoll, Oppland, Norway
🇳🇴
Diakonihjemmets Hospital, Oslo, Norway
🇳🇴
Ullevaal University Hospital, Oslo, Norway

and more 5 locations